The current financial score of Dogwood Therapeutics Inc is 5.60. Its financial status is weak, and its operating efficiency is low.
The current valuation score of Dogwood Therapeutics Inc is 6.43. Its current P/E ratio is -0.21, which is -134.97% below the recent high of 0.07 and -3151.28% above the recent low of -6.88.
The current earnings forecast score of Dogwood Therapeutics Inc is 8.00. The average price target is 13.50, with a high of 15.00 and a low of 12.00.
The current price momentum score of Dogwood Therapeutics Inc is 5.90. Currently, the stock price is trading between the resistance level at 2.39 and the support level at 1.04, making it suitable for range-bound swing trading.
The current institutional shareholding score of Dogwood Therapeutics Inc is 5.00. The latest institutional shareholding proportion is 11.07%, representing a quarter-over-quarter increase of 114.90%.
No risk assessment score is currently available for Dogwood Therapeutics Inc. The Biotechnology & Medical Research industry's average is 3.94. The company's beta value is 1.71. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.